Document Detail


Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: A multicenter study.
MedLine Citation:
PMID:  23154876     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Both baseline predictive factors and viral response at week 4 of therapy are reported to have high predictive ability for sustained virologic response to peginterferon and ribavirin combination therapy in patients with hepatitis C virus (HCV) genotype 1. However, it is not clear how these baseline variables and week 4 response should be combined to predict sustained virologic response. In this multicenter study, the authors investigated the impact of baseline predictive factors on the predictive value of week 4 viral response. Receiver-operating characteristic curve analyses were performed to evaluate the ability of week 4 reduction in HCV RNA levels to predict sustained virologic response in 293 Japanese patients infected with HCV genotype 1b. Analyses were performed in all patients and in patient subgroups stratified according to baseline variables. Overall, week 4 viral reduction demonstrates a high predictive ability for sustained virologic response. The sensitivity, specificity, positive predictive value (PPV), negative predictive value, and accuracy were higher than those of viral reduction at week 12. However, the best cut-off levels differ depending on the baseline factors and they were lower in patients with unfavorable baseline predictors. When patients had the TG/GG rs8099917 genotype, the best cut-off was markedly low with low PPV. Week 4 viral response can be a predictor of sustained virologic response in patients with HCV genotype 1 and is better than week 12 viral response. However, the cut-off levels should be modified based on the baseline predictive variables. J. Med. Virol. 85:65-70, 2012. © 2012 Wiley Periodicals, Inc.
Authors:
Hidenori Toyoda; Takashi Kumada; Noritomo Shimada; Koichi Takaguchi; Tatsuya Ide; Michio Sata; Hiroyuki Ginba; Kazuhiro Matsuyama; Namiki Izumi
Related Documents :
22984206 - Response to raltegravir-based salvage therapy in hiv-infected patients with hepatitis c...
22994166 - Effectiveness of a risk screener in identifying hepatitis c virus in a primary care set...
21963516 - Genomic risk of hepatitis c-related hepatocellular carcinoma.
23466596 - A re-assessment of the epidemiology and patient characteristics of hepatitis d virus in...
2513736 - Apolipoprotein ai is a serum and tissue marker of liver fibrosis in alcoholic patients.
12363466 - Passive active prophylaxis against hepatitis b in children with acute lymphoblastic leu...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of medical virology     Volume:  85     ISSN:  1096-9071     ISO Abbreviation:  J. Med. Virol.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2012-11-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7705876     Medline TA:  J Med Virol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  65-70     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Wiley Periodicals, Inc.
Affiliation:
Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Molecular analysis of hepatitis B virus in Bulgaria.
Next Document:  Comparison of two commercial ELISA systems for evaluating anti-EBNA1 IgG titers.